2. Academic Validation
  3. Phenibut ( β-Phenyl- γ-aminobutyric Acid) Dependence and Management of Withdrawal: Emerging Nootropics of Abuse

Phenibut ( β-Phenyl- γ-aminobutyric Acid) Dependence and Management of Withdrawal: Emerging Nootropics of Abuse

  • Case Rep Psychiatry. 2018 Apr 30;2018:9864285. doi: 10.1155/2018/9864285.
Tania Ahuja 1,  Ofole Mgbako 2,  Caroline Katzman 3,  Allison Grossman 4
Affiliations

Affiliations

  • 1 Department of Pharmacy, New York University Langone Health, 550 First Avenue, New York, NY 10016, USA.
  • 2 Department of Medicine, New York University Langone Health, 550 First Avenue, New York, NY 10016, USA.
  • 3 New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.
  • 4 Department of Psychiatry, New York University Langone Health, 550 First Avenue, New York, NY 10016, USA.
PMID: 29854531 DOI: 10.1155/2018/9864285
Abstract

This case report describes the development of withdrawal from phenibut, a gamma-aminobutyric acid-receptor type B agonist. Although phenibut is not an FDA-approved medication, it is available through online retailers as a nootropic supplement. There are reports of dependence in patients that misuse phenibut. We report a case in which a patient experienced withdrawal symptoms from phenibut and was successfully treated with a baclofen taper. This case report highlights the development of phenibut use disorder with coingestion of alcohol and potential management for phenibut withdrawal. We believe clinicians must be aware of how phenibut dependence may present and how to manage the withdrawal syndrome.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z